A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjects

Journal of Allergy and Clinical Immunology

Volumn 122, Issue 3, 2008, Pages 544-549

  Tripp, Kenneth ^a   McVicar, William K ^a   Nair, Parameswaran ^b   Corren, Jonathan ^c   Pleskow, Warren W ^d   Goodwin, Elizabeth ^a   Baumgartner, Rudolf A ^a   Hanrahan, John P ^a  

^a SUNOVION PHARMACEUTICALS INC   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c Allergy Research Foundation   (United States)

^d NONE

Author keywords

Asthma; cumulative dose; efficacy; levalbuterol HFA MDI; racemic albuterol HFA MDI; relative potency; safety

Indexed keywords

LEVALBUTEROL; SALBUTAMOL;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; HEART RATE; HUMAN; LUNG FUNCTION; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RACEMIZATION; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HEART RATE; HUMANS; HYDROCARBONS, FLUORINATED; MALE; METERED DOSE INHALERS; SPIROMETRY;

EID: 50649103028     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2008.06.015     Document Type: Article

References (16)

1. National Heart, Lung, and Blood Institute. Guidelines for the diagnosis and management of asthma (1997), National Institutes of Health, Bethesda (MD) Report no. 97-4051
2. National Heart, Lung, and Blood Institute, World Health Organization. Global strategy for asthma management and prevention. 1995. Available at: http://www.nhlbi.nih.gov/guidelines/archives/epr-2/asth_archive.pdf. Accessed December 15, 2006.
3. United Nations Environment Programme. Montreal protocol on substances that deplete the ozone layer: 1991 assessment: report of the technology and economic assessment panel. 1991. Available at: http://www.unep.org/ozone. Accessed July 2, 2007.
4. Lotvall J., Palmqvist M., Arvidsson P., Maloney A., Ventresca G.P., and Ward J. The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol 108 (2001) 726-731
5. Penn R.B., Frielle T., McCullough J.R., Aberg G., and Benovic J.L. Comparison of R-, S-, and RS-albuterol interaction with human beta 1- and beta 2-adrenergic receptors. Clin Rev Allergy Immunol 14 (1996) 37-45
6. Nelson H.S., Bensch G., Pleskow W.W., DiSantostefano R., DeGraw S., Reasner D.S., et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol 102 (1998) 943-952
7. Nelson H.S. Clinical experience with levalbuterol. J Allergy Clin Immunol 104 suppl (1999) S77-S84
8. Berger W.E., Milgrom H., Skoner D.P., Tripp K., Parsey M.V., and Baumgartner R.A. Evaluation of levalbuterol metered dose inhaler in pediatric patients with asthma: a double-blind, randomized, placebo- and active-controlled trial. Curr Med Res Opin 22 (2006) 1217-1226
9. Finney D. Statistical methods in biological assay. 3rd ed. (1978), Charles Griffin and Co LTD, London
10. Parameswaran K. Concepts of establishing clinical bioequivalence of chlorofluorocarbon and hydrofluoroalkane beta-agonists. J Allergy Clin Immunol 104 suppl (1999) S243-S245
11. Milgrom H., Skoner D., Bensch G., Kim K., Claus R., and Baumgartner R. Low-dose levalbuterol in children with asthma: safety and efficacy compared with placebo and racemic albuterol. J Allergy Clin Immunol 108 (2001) 938-945
12. Maier G., Rubino C., Hsu R., Grasela T., and Baumgartner R.A. Population pharmacokinetics of (R)-albuterol and (S)-albuterol in pediatric patients aged 4-11 years with asthma. Pulm Pharmacol Ther 20 (2007) 534-542
13. Fishwick D., Bradshaw L., Macdonald C., Beasley R., Gash D., Bengtsson T., et al. Cumulative and single-dose design to assess the bronchodilator effects of beta2-agonists in individuals with asthma. Am J Respir Crit Care Med 163 (2001) 474-477
14. Britton J., and Tattersfield A. Comparison of cumulative and non-cumulative techniques to measure dose-response curves for beta agonists in patients with asthma. Thorax 39 (1984) 597-599
15. Ahrens R.C., Hendeles L., Clarke W.R., Dockhorn R.J., Hill M.R., Vaughan L.M., et al. Therapeutic equivalence of Spiros dry powder inhaler and Ventolin metered dose inhaler. A bioassay using methacholine. Am J Respir Crit Care Med 160 (1999) 1238-1243
16. US Food and Drug Administration. Guideline for industry dose response information to support drug registration. Available at: http://www.fda.gov/Cder/guidance/iche4.pdf. Accessed November 30, 2007.